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Abstract
Background:  Vitamin D has been shown to exert manifold immunomodulatory effects. Type 1
diabetes mellitus (T1DM) is regarded to be immune-mediated and vitamin D prevents the
development of diabetes in the NOD mouse. We studied the association between T1DM and the
initiation codon polymorphism in exon 2 of the vitamin D receptor gene in a Japanese population.
We also investigated associations between the vitamin D receptor polymorphism and GAD65-
antibody (Ab) positivity. We carried out polymerase chain reaction-restriction fragment length
polymorphism analysis in 110 Japanese T1DM patients and 250 control subjects. GAD65 antibodies
were assessed in 78 patients with T1DM.
Results:  We found a significantly higher prevalence of the F allele / the FF genotype in the patients
compared to the controls (P = 0.0069 and P = 0.014, respectively). Genotype and allele frequencies
differed significantly between GAD65-Ab-positive patients and controls (P = 0.017 and P = 0.012,
respectively), but neither between GAD65-Ab-negative patients and controls (P = 0.68 and P =
0.66, respectively) nor between GAD65-Ab-positive and -negative patients (P = 0.19 and P = 0.16,
respectively).
Conclusions:  Our findings suggest that the vitamin D receptor initiation codon polymorphism
influences genetic susceptibility to T1DM among the Japanese. This polymorphism is also associated
with GAD65-Ab-positive T1DM, although the absence of a significant difference between GAD65-
Ab-negative patients and controls might be simply due to the small sample size of patients tested
for GAD65 antibodies.
Background
Type 1 diabetes mellitus (T1DM) is a multifactorial dis-
ease with a strong genetic component [1]. The main ge-
netic contribution to T1DM susceptibility lies in the
major histocompatibility complex (MHC) on the short
arm of chromosome 6; several non-MHC chromosomal
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regions are also involved [2]. Several approaches have
been used to identify T1DM susceptibility regions, in-
cluding case-control studies of candidate genes [human
leukocyte antigen (HLA), insulin gene regulatory region,
interleukin-1 receptor type 1 (ILIR1)] [3,4,5,6], com-
bined linkage and association-based studies of candidate
genes [cytotoxic T lymphocyte associated-4 (CTLA-4)]
[7], and systematic total genome searches in addition to
analyses of individual chromosomal regions
[8,9,10,11,12,13,14,15,16].
There are clear differences in immunogenetic predispo-
sition to T1DM between countries, and disease incidence
seems to vary along with these differences in predisposi-
tion [1]. The incidence of T1DM in Southern India (10.4/
100000 cases per year) is similar to that in Asian chil-
dren in the UK and Caucasian children of European ex-
traction [17,18]. While an MHC component is apparent
[19,20] in T1DM susceptibility in Southern India, no as-
sociation with either the insulin gene [20] or ILIR1 [6]
has been found there in case-control studies. This sug-
gests possible differences in the non-MHC T1DM com-
ponent between Southern Indians and Caucasians of
European extraction. In the latter population, an associ-
ation with the insulin gene has been universally reported
[4,5,21], and an IL1R1 association with T1DM has been
reported in some Northern Europeans [6,22].
VDR gene polymorphisms influence susceptibility to os-
teoporosis [23,24,25], primary hyperparathyroidism
[26,27], and autoimmune diseases such as Graves' dis-
ease [28,29], Hashimoto's thyroiditis [30], and multiple
sclerosis [31]. Allelic variation in VDR also influences
susceptibility to T1DM in Indian Asians [17], Germans
[32], and Taiwanese [33]. There are six known polymor-
phisms in the VDR locus: an exon 2 initiation codon pol-
ymorphism, which is detected with FokI restriction
enzyme [34,35,36,37], the BsmI, Tru9I, and ApaI re-
striction fragment length polymorphisms (RFLPs) locat-
ed between exons 8 and 9 [23,38], the TaqI RFLP located
in exon 9 [23], and a poly A polymorphism downstream
of the 3' untranslated region [39,40]. There is apparently
no significant linkage disequilibrium between the FokI
polymorphism and the BsmI, ApaI, and TaqI polymor-
phisms [34,35,36,37]. In this study, we analyzed the
exon 2 initiation codon (VDR-FokI) gene polymorphism
in Japanese patients with T1DM. We also investigated
associations between this VDR polymorphism and
GAD65 antibody (Ab) status, an immune marker.
Subjects and Methods
Subjects
The study population comprised 110 unrelated Japanese
T1DM patients (50 men and 60 women) from the Tokyo
metropolitan area. T1DM was diagnosed on the basis of
sudden-onset of severe symptoms or rapid progress to
overt diabetes and dependence on exogenous insulin due
to absolute insulin deficiency, according to the 1997
Committee of the American Diabetes Association (Ex-
pert Committee on the Diagnosis and Classification of
Diabetes Mellitus, 1997) criteria. All subjects were insu-
lin-dependent at the time of the study, although their β -
cell reserve, estimated by measurement of fasting serum
C-peptide, was variable. Slowly progressive T1DM was
not included in this study. Mean age at onset of T1DM
was 26.0 ± 3.7 years (mean ± SEM). GAD65 antibodies
were assessed in 78 patients. Two hundred and fifty un-
related Japanese subjects (100 men and 150 women)
without clinical evidence or family history of diabetes
mellitus or autoimmune disease were selected as con-
trols. The controls used in the present study are identical
with the previously published controls [28,29,30]. This
study was carried out in accordance with the principles
of the Declaration of Helsinki. Informed consent was ob-
tained from patients and controls.
Genotype analysis
Genomic DNA was isolated from whole blood with the
Genomix kit (Talent, Trieste, Italy). Primers VDR2a (5'-
AGCTGGCCCTGGCACTGACTCTTGCTCT-3') and
VDR2b (5'-ATGGAAACACCTTGCTTCTTCTCCCTC-3')
and 100 ng of genomic DNA were combined in a
polymerase chain reaction (PCR) mixture to amplify a
265-bp fragment containing the polymorphism in the in-
itiation codon of VDR [34]. PCR products were digested
with FokI at 37°C for 3 h and then subjected to electro-
phoresis in 2% agarose gel containing ethidium bromide.
Cleavage of homozygous DNA carrying the FokI poly-
morphism (FF) generates 69-bp and 196-bp fragments.
Restriction endonuclease cleavage analysis of DNA het-
erozygous for the FokI polymorphism (Ff) results in un-
cleaved (265-bp) DNA as well as the 69-bp and 196-bp
products. Homozygous DNA that does not carry the FokI
polymorphism (ff) is not cleaved by FokI and appears as
a single 265-bp fragment on agarose gels.
Measurement of GAD65 antibody
GAD65 Ab was detected with a radioligand binding assay
described previously [41]. Intra- and inter-assay coeffi-
cients of variation were less than 5%. At the First Inter-
national GAD Autoantibody Workshop, our GAD65 Ab
assay yielded 100% sensitivity (% positive samples con-
firmed to be positive) and 100% specificity (% known
negative samples confirmed to be negative).
Statistical analysis
Genotypes and alleles in patients and controls were com-
pared with the Χ 2-tests for 2 ×  2 and 2 ×  3 tables and by
Fisher's exact test. Relative risk was calculated by
Woolf's method [42]. P < 0.05 was considered signifi-BMC Medical Genetics (2001) 2:7 http://www.biomedcentral.com/1471-2350/2/7
cant.  We corrrected for multiple testing using the Bon-
feroni correction.
Results
Genotype and allele frequencies of the VDR-FokI gene pol-
ymorphism in patients and controls
PCR-RFLP was used to examine VDR-FokI genotype dis-
tributions in T1DM patients and controls (Table 1). The
distribution of VDR genotypes was similar between the
male and female control subjects (data not shown). The
genotype distribution in our control subjects was similar
to that in a previously reported group of Japanese wom-
en who resided in Kagawa prefecture [25].
The distribution of genotype frequencies differed signif-
icantly between T1DM patients and controls (Χ 2 = 8.48,
2 degrees of freedom, P = 0.014), with the VDR FF geno-
type occurring more frequently in the T1DM patients.
The distribution of allele frequencies differed signifi-
cantly between T1DM patients and controls (Χ 2 = 7.29, 1
degree of freedom, P = 0.0069). The relative risk con-
ferred by at least one F allele (FF or Ff) was 2.4.
Genotype distributions among patients and controls did
not differ according to age, height, or weight (data not
shown). No significant linkage disequilibrium was de-
tected between this polymorphism and the BsmI poly-
morphism in intron 8 and exon 9 in the T1DM patients
(data not shown).
VDR-FokI gene polymorphism in GAD65-antibody-positive 
and -negative subjects
We investigated association between VDR-FokI gene
polymorphism and GAD65-Ab positivity in 78 patients
(Table 2). The distribution of genotype frequencies dif-
fered significantly between GAD65-Ab-positive patients
and controls (Χ 2 = 8.14, 2 degrees of freedom, P = 0.017).
The distribution of allele frequencies also differed signif-
icantly between GAD65-Ab-positive T1DM patients and
controls (Χ 2 = 6.32, 1 degree of freedom, P = 0.012). The
relative risk conferred by at least one F allele (FF or Ff)
was 2.0. The distribution of genotype and allele frequen-
cies did not differ significantly between GAD65-Ab-neg-
ative T1DM patients and controls (Χ 2 = 0.78, 2 degrees
of freedom, P = 0.68 and Χ 2 = 0.19, 1 degree of freedom,
P = 0.66). The genotype and allele distributions in the
GAD65-Ab-positive and -negative patients did not differ
significantly (Χ 2 = 3.36, 2 degrees of freedom, P = 0.19
and Χ 2 = 1.98, 1 degree of freedom, P = 0.16, respective-
ly).
Discussion
We found an association between the VDR-FokI poly-
morphism and T1DM in our study population. Selective
β -cell destruction, which is observed in T1DM, is thought
to be caused by a T-cell-mediated autoimmune process
[43]. Genetic susceptibility to T1DM is well established,
and certain HLA pheno- and genotypes are associated
Table 1: VDR-FokI polymorphism in study subjects
T1DM patients Controls
n = 110 n = 250
Genotype frequenciesa
FF 52(47%) 82 (33%)
Ff 52(47%) 138(55%)
ff 6 (6%) 30 (12%)
Allele frequenciesb
F 156 (71%) 302(60%)
f 64 (29%) 198(40%)
Phenotype frequenciesc
F positive 104 (95%) 220(88%)
f positive 58 (53%) 168(67%)
Values shown are the number of subjects (percentage in parentheses). 
aΧ 2 test of heterogeneity between T1DM patients and control sub-
jects. Χ 2 = 8.48, 2 degrees of freedom; P = 0.014. bΧ 2 test of hetero-
geneity between T1DM patients and control subjects. Χ 2 = 7.29, 1 
degree of freedom; P = 0.0069. cRelative risk ratio for F phenotype = 
2.4.
Table 2: VDR-FokI polymorphism in study subjects analyzed with 







n = 48 n = 30 n = 250
Genotype frequenciesa
FF 26 (54%) 10(33%) 82 (33%)
Ff 19 (40%) 18(60%) 138 (55%)
ff 3(6%) 2(7%) 30 (12%)
Allele frequenciesb
F 71 (74%) 38(63%) 302(60%)
f 25 (26%) 22(37%) 198(40%)
Phenotype frequenciesc
F positive 45 (94%) 28 (94%) 220(88%)
f positive 22 (46%) 20 (67%) 168(67%)
Values shown are the number of subjects with the percentage in pa-
rentheses. aΧ 2 test of heterogeneity between GAD65-positive T1DM 
patients and control subjects. Χ 2 = 8.14, 2 degrees of freedom; P = 
0.017. bΧ 2 test of heterogeneity between GAD65-positive T1DM pa-
tients and control subjects. Χ 2 = 6.32, 1 degree of freedom; P = 0.012. 
cRelative risk ratio for F phenotype (GAD65-positive T1DM) = 2.0.BMC Medical Genetics (2001) 2:7 http://www.biomedcentral.com/1471-2350/2/7
with T1DM; for example, HLA-DR 3 and -DR 4 in Cauca-
sian populations [43], and HLA-DR 4 and -DR 9 in Jap-
anese populations [44]. Recent genome-wide searches
and several candidate gene studies have revealed new re-
gions possibly associated with T1DM
[8,9,10,11,12,13,14,15,16,45,46].
Vitamin D hormone has important immunomodulatory
properties and influences insulin secretion [47]. This
hormone inhibits T-cell activation both in vitro and in
vivo and the secretion of IL-1, IL-2, IL-6, IL-12, TNF, and
interferon (IFN)-γ  [48,49,50,51]. These cytokines play
important roles in the development of T cells, which are
believed to be involved in the pathogenesis of several
chronic inflammatory autoimmune diseases [52]. In re-
cent studies, 1,25-dihydroxyvitamin D3 was shown to in-
hibit IL-12 production by macrophages and dendritic
cells by suppressing transcriptional activation of the p35
and p45 genes, which code for subunits of IL-12. Tran-
scriptional repression of the p40 gene is dependent on
expression of VDR [53]. In murine models, vitamin D ad-
ministration prevents development of T1DM as well as
the associated autoimmune insulitis [54]. In Bangla-
deshi subjects, vitamin D levels were found to be reduced
in those subjects most at risk for type 2 diabetes [55].
The VDR locus has been studied extensively for associa-
tion with susceptibility to osteoporosis [23,24,25], pri-
mary hyperparathyroidism [26,27], and autoimmune
diseases such as Graves' disease [28,29], Hashimoto's
thyroiditis [30], and multiple sclerosis [31]. The BsmI B
allele of VDR has been associated with reduced bone
mineral density in some studies [23,56], but not in oth-
ers [57,58], and at least one study showed the b allele of
VDR to be associated with particular subtypes of oste-
oporosis [59]. The bb genotype has been associated with
primary hyperparathyroidism in Swedish patients
[26,27] and multiple sclerosis in Japanese patients [31].
The FokI FF genotype for VDR has been associated with
both Graves' disease [28] and Hashimoto's thyroiditis
[30] in Japanese patients.
The role of the VDR gene in T1DM has also been exam-
ined [17,32]. Evidence for preferential transmission of
the VDR b allele to affected offspring has been found in
Indian Asians [17]. Pani et al. [32] detected significant
haplotype-wise extended transmission disequilibrium
for the BsmI/ApaI/TaqI,  BsmI/TaqI, and ApaI/TaqI
haplotypes in Germans; analysis of the FokI site did not
provide additional information on susceptibility. Re-
cently, Chang et al. confirmed the association of these
markers with T1DM in the Taiwanese population [33].
Allelic frequencies for this and other VDR RFLPs (ApaI,
TaqI) differ between Caucasian and Japanese subjects
[24,60]. RFLP analysis of VDR revealed that the BBAAtt
genotype is relatively common (16.7%) in Caucasian pop-
ulations and rare in Japanese populations (1.4%) [24].
Therefore, we investigated VDR-FokI polymorphism in
this study. Our investigation of VDR-FokI genotype fre-
quencies in Japanese subjects revealed that the FF geno-
type is significantly more common in T1DM patients
(47%) than in control subjects (33%), suggesting that pa-
tients with this genotype may be predisposed to T1DM
[28].
In contrast to our findings for T1DM, an increased fre-
quency of the F allele, because it encodes a VDR isoform
with higher transcriptional activity, has a beneficial ef-
fects in the prevention of osteoporosis, and should lead
to higher immunomodulatory activity of the vitamin D
hormone [61]. Recently, Colin et al. [62] demonstrated
in peripheral blood mononuclear cells with a natural
VDR genotype a direct functional consequence of the
VDR-FokI polymorphism for the action of 1,25-dihy-
droxyvitamin D3. They found that the FF genotype had a
significant lower ED50 than the Ff genotype correspond-
ing to an allele dose effect of 0.32 nM per f allele copy (P
= 0.0036), while for BsmI genotypes no differences in
ED50 were observed [62]. The apparent discrepancy
could be due to the effect of the genetic susceptibility to
T1DM and ethnic differences related to VDR-FokI allelic
prevalences as well as to environmental and geographic
variations in calcium intake, exposure to sunshine, or
other factors.
In the present study, the FF genotype (or presence of the
F allele) of the VDR-FokI polymorphism was also associ-
ated with GAD65-Ab-positive T1DM in the Japanese
population, although the absence of a significant differ-
ence between GAD65-Ab-negative patients and controls
might be simply due to the small sample size of patients
tested for GAD65 antibodies. McDermott et al. [17]
found no relation between the VDR-BsmI, -TaqI, or -
ApaI polymorphism and GAD65 Ab status in Indian
Asians. Thus, since there is apparently no linkage dise-
quilibrium between FokI polymorphism and BsmI,
ApaI, and TaqI polymorphisms [34,35,36,37], the VDR-
FokI polymorphism seems to contribute to immunologi-
cal heterogeneity of T1DM, although the mechanism re-
mains unclear. Although no in vitro or animal studies
have shown that VDR function is directly associated with
antibody production in autoimmune disease or that this
polymorphism might alter immune function, GAD65-
Ab-negative diabetes patients could be subject to a dif-
ferent disease process or a different path of clinical de-
velopment with regards to a possible VDR contribution.
Both possibilities warrant further study.BMC Medical Genetics (2001) 2:7 http://www.biomedcentral.com/1471-2350/2/7
Conclusions
In conclusion, our data indicates an association between
the VDR gene and T1DM among the Japanese. We sug-
gest that the FF genotype may predispose Japanese indi-
viduals to T1DM and that this genotype appears to be a
marker for T1DM. The role of the VDR gene polymor-
phism should be studied further in other populations,
and other polymorphisms, such as the BsmI,  ApaI,
Tru9I and TaqI polymorphisms, should be analyzed for
association with T1DM susceptibility. In addition, the
VDR-FokI polymorphism showed a possible association
with GAD65-Ab-positive T1DM. The VDR plays a role in
lymphocyte response to microorganisms (tuberculin re-
active status in pulmonary tuberculosis, leprosy etc.).
Thus, it is conceivable that it may also be involved in im-
mune response to self antigens e.g. GAD65 antibodies.
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